Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GAL 101

Next Previous
Drug Profile

GAL 101

Alternative Names: GAL-101; MRZ-99030

Latest Information Update: 04 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tel Aviv University
  • Developer Galimedix Therapeutics; Merz Pharmaceuticals GmbH
  • Class Antiglaucomas; Dipeptides; Eye disorder therapies; Neuroprotectants; Small molecules
  • Mechanism of Action Protein aggregation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Dry age-related macular degeneration; Glaucoma
  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Mar 2023 Galimedix Therapeutics plans to develop GAL 101 for oral formulation for the treatment of Dry age-related macular degeneration and Glaucoma
  • 29 Mar 2023 GAL 101 is still in Phase-I development for Glaucoma in Germany (Ophthalmic, Drops).
  • 29 Mar 2023 Thea Open Innovation and Galimedix enter into License Agreement to develop and commercialise GAL 101 for Ophthalmic disorders in Europe, the Americas, the Middle East and Africa
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top